Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

The Societal Value of Vaccination in the Age of COVID-19

(2021) David E. Bloom et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

COVID-19 pandemic related long-term chronic stress on the prevalence of depression and anxiety in the general population

(2021) Tian Qi et al.   BMC Psychiatry

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

(2021) Mark M. Painter et al.   IMMUNITY

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

(2021) Guerrieri S. et al.   JOURNAL OF NEUROLOGY

Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help

(2021) Jernej Pušnik et al.   Cell Reports

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

(2021) Maria Pia Sormani et al.   EBioMedicine

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

(2021) Daryl Geers et al.   Science Immunology

Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies

(2021) Kévin Bigaut et al.   Neurology-Neuroimmunology & Neuroinflammation

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

(2021) Anat Achiron et al.   JOURNAL OF NEUROIMMUNOLOGY

Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients

(2020) Johanna E. Huber et al.   JOURNAL OF IMMUNOLOGY

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

(2020) F. Schweitzer et al.   JOURNAL OF NEUROLOGY

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

(2020) Syed Faraz Ahmed et al.   Viruses-Basel

Lymphocyte recovery after fingolimod discontinuation in patients with MS

(2020) Sara Nagy et al.   Neurology-Neuroimmunology & Neuroinflammation

Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients

(2020) M. C. Kowarik et al.   Neurotherapeutics

Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity

(2016) Erin E. Longbrake et al.   JAMA Neurology

Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations

(2014) Yusei Miyazaki et al.   CLINICAL IMMUNOLOGY

Differential effects of fingolimod on B-cell populations in multiple sclerosis

(2014) Masakazu Nakamura et al.   Multiple Sclerosis Journal

Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study

(2014) Nele Claes et al.   PLoS One

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

(2013) G Francis et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY